Alan Winston

Imperial College London - Department of Infectious Disease

SCHOLARLY PAPERS

3

DOWNLOADS
Rank 45,087

SSRN RANKINGS

Top 45,087

in Total Papers Downloads

2,256

TOTAL CITATIONS

2

Scholarly Papers (3)

1.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Number of pages: 34 Posted: 16 Jun 2021
Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, University College London, Imperial College London, NIHR Imperial Clinical Research Facility, University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London, Imperial College London, University College London Hospitals NHS Foundation Trust - Department of Clinical Virology, University College London, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Imperial College London, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, St George’s University London - St George’s Vaccine Institute, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 1,546 (24,932)

Abstract:

Loading...

2.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Number of pages: 39 Posted: 19 Apr 2021
University of Oxford - Peter Medawar Building for Pathogen Research, GSK plc, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, NIHR Imperial Clinical Research Facility, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University College London - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, NIHR Guy's and St Thomas' Biomedical Research Centre, Imperial College London - Department of Infectious Disease, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Oxford University Hospitals NHS Foundation Trust, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, University of Oxford - Department of Paediatrics, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Imperial College London - Department of Infectious Disease, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, Imperial College London - Section of Virology, Guy's and St Thomas' NHS Foundation Trust - Harrison Wing, University of Oxford - The Jenner Institute and Independent
Downloads 663 (81,431)
Citation 2

Abstract:

Loading...

3.

COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Number of pages: 33 Posted: 27 Sep 2022
University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, St George’s University London - St George’s Vaccine Institute, Government of the United Kingdom - Department of HIV/GUM, Government of the United Kingdom - Department of HIV/GUM, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, St George’s University London - St George’s Vaccine Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Imperial College London - Section of Virology, St George’s University London - St George’s Vaccine Institute, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University College London, Imperial College London - Department of Infectious Disease, Chelsea and Westminster Hospital NHS FT, Imperial College London - Department of Infectious Disease, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton - NIHR Southampton Biomedical Research Centre, University College London - Comprehensive Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University of Surrey - Surrey Clinical Research Centre, University College London - Comprehensive Biomedical Research Centre, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 47 (799,956)

Abstract:

Loading...

SARS-CoV-2, vaccination, self-amplifying RNA, saRNA, immune response